Psoriasis Product description The Competitive Intelligence Report Psoriasis R&D Pipeline as of May 2007 provides a competitor analysis in the development pipeline of novel biologics, vaccines and small molecules directed against innovative targets in psoriasis such as tumor necrosis factor-alpha (TNF-alpha), interleukin-12 and -23, IL-15, IL-20, IL-22R, the PTH receptor and many more. Anti-TNF Competitor projects for approved TNF-antagonist antibodies Remicade (infliximab) and Enbrel (etanercept) are presented including antibodies, vaccines, proteins, small molecules with systemic and topical administration targeting TNF-alpha. Biologics A total of 16 new biologics in clinical stages of the psoriasis R&D pipeline such as antibodies, proteins, DNA and peptides in active development for treatment of psoriasis are presented including projects from preclinical to phase III stages. Targets include the PTH receptor, complement C5a, CD3, interferon alpha, PSGL-1 and AFP-R with systemic and topical drug delivery. Small molecules Generic and approved new vitamin D analogs and super-high potency steroids in including novel drug delivery application formats are presented. A total of 32 clinical stage (phase I to III) R&D small molecule projects of the psoriasis R&D pipeline are presented. Among the novel targets are HDAC, TrkA, p38 MAP kinase, PDE-IV, LFA-1, cathepsin-S, adenosine A3 receptor, RAMBA, flt-3, ICAM, selectin and many more. . Companies Among Big Pharma and Big Biotech companies engaged in development of novel psoriasis treatments are Astellas Pharma, Bristol-Myers Squibb, Johnson & Johnson (Centocor), Abbott, Boehringer Ingelheim, Bayer Schering Pharma, Amgen, UCB, Biogen, MedImmune, Novo Nordisk and Merck Serono. Product Description The present Competitive Intelligence Report of Psoriasis R&D Pipeline provides an update of a competitor evaluation in the field of of novel biologics and small molecules with systemic and topical administration used to treat psoriasis as of May 2007. The Competitor Evaluation first has been published in September 2006, but now has been completely updated. Competitor projects are listed on 11 pages in a tabular format providing Information on: - Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index - Competitor Analysis
- Anti-TNF
- Biologics in Psoriasis
- Small Molecules in Psoriasis
- No Further Activity
- About La Merie Business Intelligence
About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.
|
